

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/740,245	-,	12/18/2003	Joerg Huwyler	21382	1762
151	7590	12/09/2005	EXAMINER		
		ROCHE INC. ARTMENT	SHAMEEM, GOLAM M		
	SLAND ST		ART UNIT	PAPER NUMBER	
NUTLEY,	NJ 07110	0	1626		

DATE MAILED: 12/09/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	n No.	Applicant(s)					
	Office Action Summer	10/740,24	5	HUWYLER ET AL.					
	Office Action Summary	Examiner		Art Unit					
			M. Shameem, Ph.D.	1626					
Period fo	The MAILING DATE of this communication or Reply	appears on the	cover sheet with the c	orrespondence ad	ldress				
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR RECHEVER IS LONGER, FROM THE MAILING ansions of time may be available under the provisions of 37 CFI SIX (6) MONTHS from the mailing date of this communication to period for reply is specified above, the maximum statutory perion to reply within the set or extended period for reply will, by streply received by the Office later than three months after the med patent term adjustment. See 37 CFR 1.704(b).	G DATE OF TH R 1.136(a). In no eve n. riod will apply and will tatute, cause the appl	IS COMMUNICATION nt, however, may a reply be tim I expire SIX (6) MONTHS from cation to become ABANDONE	N. nely filed the mailing date of this c D (35 U.S.C. § 133).	•				
Status			•						
1)	Responsive to communication(s) filed on 0	7 October 2004	5						
2a)⊠		This action is n			•				
3)	Since this application is in condition for allo			secution as to the	a marite ie				
٠,١	closed in accordance with the practice und				s ments is				
Dispositi	ion of Claims								
· _	Claim(s) 1-21 is/are pending in the applica	tion							
7/12.21			nsideration						
5)	4a) Of the above claim(s) is/are withdrawn from consideration.  Claim(s) is/are allowed.								
·									
· ·	Claim(s) <u>17-70</u> is/are rejected.  Claim(s) <u>17-21</u> is/are objected to.								
8)□	Claim(s) are subject to restriction ar	nd/or election re	equirement						
,—		10/01/0/00/00/17	, and the state of						
	ion Papers								
•	The specification is objected to by the Exan		<b></b>		•				
10)	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
	Applicant may not request that any objection to		-						
11)	Replacement drawing sheet(s) including the cor The oath or declaration is objected to by the	•	• , ,	•	` '				
Priority (	under 35 U.S.C. § 119								
	Acknowledgment is made of a claim for fore	aian nriarity und	dar 25     C C S 440(-)	v(d) or (f)					
	☐ All b)☐ Some * c)☐ None of:	eigii pilonty und	iei 35 U.S.C. § 119(a)	)-(u) or (r).					
a)	1.☐ Certified copies of the priority docum	ante hava haa	n received						
	Certified copies of the priority docum     Certified copies of the priority docum			on No					
	3. Copies of the certified copies of the		• •	' <u></u>	Stago				
	application from the International Bu			ou iii tilis ivational	Stage				
* 9	See the attached detailed Office action for a	•		٠d					
`	200 and and and addition of the addition for a		TOU COPICO HOL TECCIVE						
					•				
Attachmen	• •								
	e of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948)		4) Interview Summary Paper No(s)/Mail Da						
	e of Draπsperson's Patent Drawing Review (P10-948) mation Disclosure Statement(s) (PT0-1449 or PT0/SE		5) Notice of Informal P		O-152)				
	er No(s)/Mail Date	,	6) Other:						

Page 2

#### **DETAILED ACTION**

### Status of Claims

Claims 1-21 are currently pending in the application.

Receipt is acknowledged of amendment / response filed on October 07, 2005 and that has been entered.

## Response to Arguments

Applicant's arguments [to withdrawal of the rejection of claims 1-21 under 35 U.S.C. § 102(b)] have been fully considered and found persuasive with respect to the above rejection and the rejection is hereby withdrawn. However, Applicant's other arguments [to withdrawal of the rejection of claims 1-16 under the judicially created doctrine of obviousness-type double patenting over US 6,462,198] have been considered and found unpersuasive due to the following reasons:

Claims 1-16 are rejected under the judicially created doctrine of obviousness-type double patenting, as being unpatentable over claims 1-23 of US 6,462,198 of record and the rejection has been maintained for the reasons given in the last office action mailed on 07/05/2005. Applicant's arguments have been fully considered but are not deemed persuasive because Applicants' arguments unsupported by objective and competent factual evidence are entitled to little weight. In re Greenfield 197 USPQ 227. In re Lindner 173 USPQ 356. Applicant alleges, "the instant claims have unobvious properties over those claimed in the '198 patent" [Response, page 4]. This assessment is speculation on applicant's behalf because US '198 patent broadly teaches the generic compounds and compositions having similar mGlu1 receptor agonists and/or antagonist activity (see column 12), which are within the boundaries of the instantly claimed

Art Unit: 1626

compounds and compositions. Therefore, the disclosure of US '198 that teach many permutation and combination substitutions (including various Markush variable substitutions, such as B, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> etc), which would easily place Applicants invention in possession of the public at the time of Applicants invention was filed. The indiscriminate selection of "some" among "many" is prima facie obvious, In re Lemin, 141 USPQ 814 (1964). Therefore, in the instant case, one skilled in the chemical art would be motivated to choose to replace variable substitutions in permutation and combinations in core structure to obtain the desired products in view of the known teaching of the art. The claimed compounds are so closely related structurally to the homologous and /or analogous compounds of the reference as to be structurally obvious therefore in the absence of any unobviousness or unexpected properties. Moreover, any other differences are but obvious structural modifications, which would be apparent to one skilled in the chemical art that can use similar substitutions, would expect to have the same or essentially the same results. Since the core xanthene ring of the compound of formula (I) is not novel and the novelty (if there is any) belongs to the selection of different variable substitutions, a great caution should be exercised to determine the patentability of the claimed invention. Therefore, in the absence of objective evidence showing an unexpected result, the obviousness-type double patenting rejection is deemed to be proper and hence, this rejection must be maintained.

#### **Objections**

Claims 17-21 are objected to as being dependent upon a rejected base claim 1, but would be allowable (after filing Terminal Disclaimer) if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Therefore, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

## Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Golam Shameem, Ph.D. whose telephone number is (571) 272-0706. The examiner can normally be reached on Monday-Thursday from 6:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane, can be reached at (571) 272-0699. The Unofficial fax phone number for this Group is (703) 308-7921. The Official fax phone number for this Group is (571) 273-8300.

When filing a FAX in Technology Center 1600, please indicate in the Header (upper right) "Official" for papers that are to be entered into the file, and "Unofficial" for draft documents and other communications with the PTO that are not for entry into the file of the application. This will expedite processing of your papers.

Art Unit: 1626

89.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [joseph.mcKane@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR only. For more information about the pair system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866) 217-9197.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (571) 272-1600.

Golam M M Shameem, Ph.D. Primary Examiner Art Unit 1626 Technology Center 1600

GOLAM M. M. SHAMEEM, PH.D.
PRIMARY EXAMINER